Metabolism - Clinical and Experimental This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Statin treatment reduces leucine turnover, but does not affect endogenous production of beta-hydroxy-beta-methylbutyrate (HMB)
Statins, or hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, are one of the most commonly prescribed medications for lowering cholesterol. Myopathic side-effects ranging from pain and soreness to critical rhabdomyolysis are commonly reported and often lead to discontinuation. The pathophysiological mechanism is, in general, ascribed to a downstream reduction of Coenzyme Q10 synthesis, resulting in mitochondrial dysfunction. HMG-CoA is a metabolite of leucine and its corresponding keto acid α-ketoisocaproic acid (KIC) and beta-hydroxy-beta-methylbutyrate (HMB), however little is known about the changes in...
Source: Metabolism - Clinical and Experimental - April 25, 2024 Category: Biomedical Science Authors: Martin Hagve, Suzette L. Pereira, Dillon K. Walker, Marielle P.K.J. Engelen, Nicolaas E.P. Deutz Source Type: research

Obesity and dyslipidemia in early life: Impact on cardiometabolic risk
Childhood obesity with its growing prevalence worldwide presents one of the most important health challenges nowadays. Multiple mechanisms are involved in the development of this condition, as well as in its associations with various cardiometabolic complications, such as insulin resistance, diabetes, metabolic dysfunction-associated steatotic liver disease and cardiovascular diseases. Recent findings suggest that childhood obesity and associated dyslipidemia at least partly originate from epigenetic modifications that take place in the earliest periods of life, namely prenatal and perinatal periods. (Source: Metabolism - ...
Source: Metabolism - Clinical and Experimental - April 21, 2024 Category: Biomedical Science Authors: Aleksandra Zeljkovic, Jelena Vekic, Aleksandra Stefanovic Tags: Review Source Type: research

O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36
Nonalcoholic fatty liver disease (NAFLD) and its progressive variant, nonalcoholic steatohepatitis (NASH), constitute a burgeoning worldwide epidemic with no FDA-approved pharmacotherapies. The multifunctional immunometabolic receptor, fatty acid translocase CD36 (CD36), plays an important role in the progression of hepatic steatosis. O-GlcNAcylation is a crucial posttranslational modification that mediates the distribution and function of CD36, but its involvement in NAFLD remains poorly understood. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - April 18, 2024 Category: Biomedical Science Authors: Hanlong Zhu, Tianming Zhao, Si Zhao, Suzhen Yang, Kang Jiang, Shupei Li, Ying Kang, Zhuoxin Yang, Jiajia Shen, Si Shen, Hui Tao, Ji Xuan, Miaofang Yang, Bing Xu, Fangyu Wang, Mingzuo Jiang Source Type: research

Virus-induced diabetes mellitus, revisiting infection etiology in light of SARS-CoV-2
Diabetes mellitus (DM) is comprised of two predominant subtypes: type 1 diabetes mellitus (T1DM), accounting for approximately 5  % of cases worldwide and resulting from autoimmune destruction of insulin-producing β-cells, and type 2 (T2DM), accounting for approximately 95 % of cases globally and characterized by the inability of pancreatic β-cells to meet the demand for insulin due to a relative β-cell deficit in the setting of peripheral insulin resistance. Both types of DM involve derangement of glucose metabolism and are metabolic diseases generally considered to be initiated by a combination of genetic and envi...
Source: Metabolism - Clinical and Experimental - April 17, 2024 Category: Biomedical Science Authors: Sundararaj Stanleyraj Jeremiah, Abu Saleh Md Moin, Alexandra E. Butler Tags: Review Source Type: research

Corrigendum to “Imeglimin improves systemic metabolism by targeting brown adipose tissue and gut microbiota in obese model mice” [Metabolism 153 (April 2024) 155796]
The authors regret that in the original version of the article, the HE staining images of HFD and HFD  + Ime in Fig. 2 section O were inadvertently presented inversely. The corrected version is shown below. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - April 15, 2024 Category: Biomedical Science Authors: Motoharu Awazawa, Maya Matsushita, Ikumi Nomura, Naoki Kobayashi, Miwa Tamura-Nakano, Yuriko Sorimachi, Keiyo Takubo, Kohjiro Ueki Tags: Corrigendum Source Type: research

Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Glucagon receptor agonism is currently explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The metabolic effects of glucagon receptor agonism may in part be mediated by increases in circulating levels of Fibroblast Growth Factor 21 (FGF21) and Growth Differentiation Factor 15 (GDF15). The effect of glucagon agonism on FGF21 and GDF15 levels remains uncertain, especially in the context of elevated insulin levels commonly observed in metabolic diseases. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - April 15, 2024 Category: Biomedical Science Authors: Michael M. Richter, Ida M. Kemp, Sara Heeb øll, Marie Winther-Sørensen, Sasha A.S. Kjeldsen, Nicole J. Jensen, Janus D. Nybing, Frederik H. Linden, Erik Høgh-Schmidt, Mikael P. Boesen, Sten Madsbad, Frank Vinholt Schiødt, Kirsten Nørgaard, Signe Schm Source Type: research

Hepatic Klf10-Fh1 axis promotes exercise-mediated amelioration of NASH in mice
Exercise is an effective non-pharmacological strategy for the treatment of nonalcoholic steatohepatitis (NASH), but the underlying mechanism needs further investigation. Kruppel-like factor 10 (Klf10) is a transcriptional factor that is expressed in multiple tissues including liver, whose role in NASH is not well defined. In our study, exercise induces hepatic Klf10 expression through the cAMP/PKA/CREB pathway. Hepatocyte-specific knockout of Klf10 (Klf10LKO) increases lipid accumulation, cell death, inflammation and fibrosis in NASH diet-fed mice and reduces the protective effects of treadmill exercise against NASH, while...
Source: Metabolism - Clinical and Experimental - April 12, 2024 Category: Biomedical Science Authors: Hong-Yang Luo, Wang-Jing Mu, Min Chen, Jie-Ying Zhu, Yang Li, Shan Li, Lin-Jing Yan, Ruo-Ying Li, Meng-Ting Yin, Xin Li, Hu-Min Chen, Liang Guo Source Type: research

Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution
This study aims to explore the role and mechanism of Trem2 in MASLD. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - April 10, 2024 Category: Biomedical Science Authors: Wenjie Yu, Yu Zhang, Linfeng Sun, Wei Huang, Xiangdong Li, Nan Xia, Xuejiao Chen, Likalamu Pascalia Wikana, Yuhao Xiao, Minhao Chen, Sheng Han, Ziyi Wang, Liyong Pu Source Type: research

Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)- α/γ agonist, has been used to treat metabolic diseases such as insulin resistance and diabetic dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD). SARO, administered at a dose of 4 mg/day, has been consistently studied in clinical trials with different time points ranging fr om 4 to 24 weeks with NAFLD patients. Due to its PPAR-γ agonistic action, SARO prevents adipose tissue-mediated fatty acid delivery to the liver by increasing insulin sensitivity and regulating adiponectin and leptin levels in adipose tissue. (Sou...
Source: Metabolism - Clinical and Experimental - April 10, 2024 Category: Biomedical Science Authors: Devaraj Ezhilarasan Tags: Review Source Type: research

Role of mitochondria in pathogenesis and therapy of renal fibrosis
Renal fibrosis, specifically tubulointerstitial fibrosis, represents the predominant pathological consequence observed in the context of progressive chronic kidney conditions. The pathogenesis of renal fibrosis encompasses a multifaceted interplay of mechanisms, including but not limited to interstitial fibroblast proliferation, activation, augmented production of extracellular matrix (ECM) components, and impaired ECM degradation. Notably, mitochondria, the intracellular organelles responsible for orchestrating biological oxidation processes in mammalian cells, assume a pivotal role within this intricate milieu. (Source: ...
Source: Metabolism - Clinical and Experimental - April 10, 2024 Category: Biomedical Science Authors: Xiaodong Zhao, Yunkuo Li, Jinyu Yu, Haolin Teng, Shouwang Wu, Yishu Wang, Honglan Zhou, Faping Li Source Type: research

Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies
Weight loss and lifestyle intervention improve glucose tolerance delaying the onset of type 2 diabetes (T2D), but individual responses are highly variable. Determining the predictive factors linked to the beneficial effects of weight loss on glucose tolerance could provide tools for individualized prevention plans. Thus, the aim was to investigate the relationship between pre-intervention values of insulin sensitivity and secretion and the improvement in glucose metabolism after weight loss. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - April 8, 2024 Category: Biomedical Science Authors: S. Sabatini, J.J. Nolan, G. O'Donoghue, A. Kennedy, John Petrie, Mark Walker, D.J. O'Gorman, A. Gastaldelli Source Type: research

Editorial Board
(Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - April 4, 2024 Category: Biomedical Science Source Type: research

Kr üppel-like factor 10 protects against metabolic dysfunction-associated steatohepatitis by regulating HNF4α-mediated metabolic pathways
This study aimed to el ucidate the precise role of hepatic KLF10 in developing metabolic dysfunction-associated steatohepatitis (MASH) in diet-induced obese mice. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - April 4, 2024 Category: Biomedical Science Authors: Xiaoli Pan, Shuwei Hu, Yanyong Xu, Raja Gopoju, Yingdong Zhu, Fathima N. Cassim Bawa, Hui Wang, Jiayou Wang, Zaid Batayneh, Alyssa Clark, Yuhao Zeng, Li Lin, Xinwen Wang, Liya Yin, Yanqiao Zhang Source Type: research

Interplay of CD36, autophagy, and lipid metabolism: insights into cancer progression
CD36, a scavenger receptor B2 that is dynamically distributed between cell membranes and organelle membranes, plays a crucial role in regulating lipid metabolism. Abnormal CD36 activity has been linked to a range of metabolic disorders, such as obesity, nonalcoholic fatty liver disease, insulin resistance and cardiovascular disease. CD36 undergoes various modifications, including palmitoylation, glycosylation, and ubiquitination, which greatly affect its binding affinity to various ligands, thereby triggering and influencing various biological effects. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - March 26, 2024 Category: Biomedical Science Authors: Yuxuan Yang, Xiaokun Liu, Di Yang, Lianhui Li, Sheng Li, Sen Lu, Ning Li Source Type: research

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Over the past decade, there have been several guideline updates for the diagnosis and management of non-alcoholic fatty liver disease (NAFLD), which is the most common chronic liver disease affecting approximately one-third of the world's population [1 –3]. These changes were necessitated by our evolving understanding of the disease, the name of which has also recently been changed from “NAFLD”, resulting from a lack of mechanistic understanding to metabolic dysfunction-associated steatotic liver disease (MASLD), and from non-alcoholic steat ohepatitis (NASH) to metabolic dysfunction-associated steatohepatitis (MASH)...
Source: Metabolism - Clinical and Experimental - March 18, 2024 Category: Biomedical Science Authors: Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, Vasilios Kotsis, Rohit Loomba, Arun J. Sanyal, Christos S. Mantzoros Tags: Editorial Source Type: research